Our results highlight obesity-related differences in the regulation of responses to O3 by IL-33, and emphasize the need for attention to the role of obesity and the gut microbiome in the development of asthma pharmaceuticals, including but potentially not limited to those that target the IL-33/ST2 pathway. Here, IL1RL1 is linked to obesity disorder.